Post-hip fracture use of prescribed calcium plus vitamin D or vitamin D supplements and antiosteoporotic drugs is associated with lower mortality: A nationwide study in Finland

Journal of Bone and Mineral Research

Volumn 26, Issue 8, 2011, Pages 1845-1853

  Nurmi Lüthje, Ilona ^a,b   Sund, Reijo ^c   Juntunen, Merja ^c   Lüthje, Peter ^d  

^a Center for Injury and Violence Prevention   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d North Kymi Hospital   (Finland)

Author keywords

antiosteoporotic drugs; calcium; hip fracture; mortality; vitamin D

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; PARATHYROID HORMONE[1-34]; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D;

AGED; ARTICLE; FEMALE; FINLAND; HIP FRACTURE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; OSTEOPOROSIS; SURVIVAL; VITAMIN SUPPLEMENTATION;

AGED; AGED, 80 AND OVER; CALCIUM; DIETARY SUPPLEMENTS; FEMALE; FINLAND; HIP FRACTURES; HUMANS; MALE; OSTEOPOROSIS; PATIENT DISCHARGE; PRESCRIPTION DRUGS; PROPORTIONAL HAZARDS MODELS; VITAMIN D;

EID: 79955539555     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.375     Document Type: Article

References (45)

1. Johnell O, Kanis KA,. An estimate of worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int. 2006; 17: 1726-1733. (Pubitemid 44607392)
2. Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int. 2000; 11: 669-674.
3. Office of the Surgeon General, US Department of Health and Human Services. Bone health and osteoporosis: a report of the Surgeon General. Available at: Accessed September 13, 2010.
4. Rabenda V, Vanoverloop J, Fabri V, et al. Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Joint Surg Am. 2008; 90: 2142-2214.
5. Cree MW, Juby AG, Carriere KC,. Mortality and morbidity associated with osteoporosis drug treatment following hip fracture. Osteoporos Int. 2003; 14: 922-928.
6. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. HORIZON recurrent fracture trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357: 1799-1809. (Pubitemid 350044800)
7. Cameron ID, Chen JS, March LM, et al. Hip fracture causes excess mortality owing to cardiovascular and infectious disease in institutionalized older people: a prospective 5-year study. J Bone Miner Res. 2010; 4: 866-872.
8. Beaupre LA, Morrish DW, Hanley DA, et al. Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporosis Int. 2011; 22: 983-991.
9. Sambrook PN, Cameron ID, Chen JS, et al. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporosis Int. 2010; Published online October 20, 2010; DOI: 10.1007/s00198-010-1444-6.
10. Bolland MJ, Grey AB, Gamble GD, Reid IR,. Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrin Metab. 2010; 95: 1174-1181.
11. Nurmi-Lüthje I, Lüthje P, Kaukonen JP, Kataja M, Kuurne S, Naboulsi H,. Post-fracture prescribed calcium and vitamin D supplements alone or, in females, with concomitant anti-osteoporotic drugs is associated with lower mortality in elderly hip fracture patients. Drugs Aging. 2009; 26: 409-421.
12. Sund R, Juntunen M, Lüthje P, Huusko T, Häkkinen U,. Monitoring the performance of hip fracture treatment in Fintand. Ann Med. 2011; 43 (Suppl 1): S39-46.
13. Sund R,. Methodological perspectives for register-based health system performance assessment. Developing a hip fracture monitoring system in Finland. Research report 174. National Research and Development Centre for Welfare and Health. Available at: Accessed September 13, 2010.
14. Sund R, Nurmi-Lüthje I, Lüthje P, Tanninen S, Narinen A, Keskimäki I,. Comparing properties of audit data and routinely collected register data in case of performance assessment of hip fracture treatment in Finland. Methods Inf Med. 2007; 46: 558-566. (Pubitemid 47598974)
15. National guidelines. Treatment of hip fracture patients. Duodecim. 2006; 122: 358-379. Available at:. Accessed September 13, 2010.
16. Lüthje P, Nurmi-Lüthje I, Kaukonen J-P, Kuurne S, Naboulsi H, Kataja M,. Undertreatment of osteoporosis following hip fracture in the elderly. Arch Gerontol. 2009; 49: 153-157.
17. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK,. The components of excess mortality after hip fracture. Bone. 2003; 32: 468-473. (Pubitemid 39665705)
18. Colón-Emeric CS, Mesenbrink P, Lyles KW, et al. Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res. 2010; 25: 91-97.
19. Cranney A, Weiler HA, O'Donnell S, Puil L,. Summary of evidence-based review on vitamin D efficacy and safety in relation to bone health. Am J Clin Nutr. 2008; 88: 513S-519S.
20. Garland CF, Gorham ED, Mohr SB, Garland FC,. Vitamin D for cancer prevention: global perspective. AEP. 2009; 19: 468-483.
21. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ., 2009; 339: b3692.
22. Laaksi I, Ruohola JP, Tuohimaa P, et al. An association of serum vitamin D concentration <40nmol/L with acute respiratory tract infection in young Finnish men. Am J Clin Nutr. 2007; 86: 714-717. (Pubitemid 47435839)
23. van Ettern E, Decallone B, Verlinden L, Verstuyf A, Bouillon R, Mathieu C,. Analogs of 1alpha 25-dihydroxyvitamin D3 as pluripotent immunomodulators. J Cell Biochem. 2003; 88: 223-226. (Pubitemid 36119890)
24. Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ,. Baseline serum 25-hydroxy vitamin D is predictive of future glycaemic status and insulin resistance: the MRC Ely prospective study 1990-2000. Diabetes. 2008; 57: 2619-2626.
25. Zitterman A, Koerfer R,. Vitamin D in the prevention and treatment of coronary heart disease. Curr Opin Clin Nutr Metab Care. 2008; 1: 752-757.
26. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin D and 1.25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008; 168: 1340-1349. (Pubitemid 351930842)
27. Ginde AA, Scragg R, Schwartz RS, Camargo CA,. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults. JAGS. 2009; 57: 1595-1603.
28. Melamed ML, Michos ED, Post W, Astor B,. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008; 168: 1629-1637.
29. LaCroix AZ, Kotchen J, Anderson G, et al. Calcium plus vitamin D supplementation and mortality in postmenopausal women: The Women Health Initiative calcium-vitamin D randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2009; 64: 559-567.
30. Kaluza J, Orsini N, Levitan EB,. Dietary calcium and magnesium intake and mortality: a prospective study of men. Am J Epidemiol. 2010; 171: 801-807.
31. Bolland MJ, Barber PA, Doughty RN, et al. Vascular events in healthy older women receiving calcium supplementation: randomized controlled trial. BMJ. 2008; 336: 262-268.
32. Bolland MJ, Avenell A, Baron JA, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010; 341: c3691.
33. Devold HM, Doung GM, Tverdal A, et al. Prescription of anti-osteoporosis drugs during 2004-2007-a nationwide register study in Norway. Eur J Clin Pharmacol. 2009; 66: 299-306.
34. National guidelines. Osteoporosis. Duodecim. 2000; 116: 1771-1788 Available at:. Accessed September 13, 2010.
35. Rizzoli R, Burlet N, Cahall D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone. 2008; 42: 841-847.
36. Cermak K, Shumelinsky F, Alexiou J, Gebhart MJ,. Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy. Clin Orthop Relat Res. 2009; 468: 1991-1996.
37. Bhuriya R, Singh M, Molnar J, Arora R, Khosla S,. Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol. 2010; 142: 213-217.
38. Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010; 362: 1761-1771.
39. Watts NB, Diab DL,. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrin Metab. 2010; 95: 1555-1565. Published online February 19; 2010; DOI: 10.1210/jc.2009-1947.
40. Nurmi I, Kaukonen JP, Lüthje P, et al. Half of the patients with an acute hip fracture suffer from hypovitaminosis D: a prospective study in South-East of Finland. Osteoporos Int. 2005; 16: 2018-2024. (Pubitemid 41790922)
41. Kauppi M, Impivaara O, Heliövaara M, Marniemi J, Montonen J, Jula A,. Vitamin D status and common risk factors for bone fragility as determinants of quantitative ultrasound variables in a nationally representative population sample. Bone. 2009; 45: 119-124.
42. Rodan G, Reszka A, Golub E, Rizzoli R,. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin. 2004; 20: 1291-1300. (Pubitemid 39120794)
43. Jones G,. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008; 88: (suppl): 582S-586S.
44. Reid IR, Schooler BA, Hannon SF, Ibbertson HK,. The acute biochemical effects of four proprietary calcium supplements. Aust N Z J Med. 1986; 16: 193-197. (Pubitemid 17184768)
45. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006; 333: 15-18. (Pubitemid 44406838)